NCT00435448

Study of the Efficacy and Safety of Lonidamine for the Treatment of Symptomatic Benign Prostatic Hyperplasia

A Randomized Phase 3, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Lonidamine for the Treatment of Symptomatic Benign Prostatic Hyperplasia

• Status: Terminated
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 480 (planned)
• Sponsor: Threshold Pharmaceuticals · Industry
• Sex: Male
• Age: 50 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the efficacy of lonidamine (50mg, 150mg) compared to placebo in subjects with symptomatic BPH.

Conditions

• Benign Prostatic Hyperplasia
• Enlarged Prostate

Interventions

Type	Name	Description
DRUG	Lonidamine

Timeline

• Start date: 2005-06-01
• Primary completion: 2006-12-01
• Completion: 2006-12-01
• First posted: 2007-02-15
• Last updated: 2009-04-29

Locations

58 sites across 4 countries: Germany, Hungary, Italy, Poland